A clinical Study to evaluate the safety and pharmacokinetics/pharmacodynamics(PK/PD) of YH4808 after repeated Oral administration and Postprandial state in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Group1 1. adminitration of YH4808 dose1, bid for 2weeks 2. wash-out period for 3weeks between period1 and period2 3. adminitration of YH4808 dose2, qd for 2weeks
Group2 1. adminitration of YH4808 dose2, qd for 2weeks 2. wash-out period for 3weeks between period1 and period2 3. adminitration of YH4808 dose1, bid for 2weeks
Group3 1. adminitration of YH4808 dose2, bid for 2weeks 2. wash-out period for 3weeks between period1 and period2 3. adminitration of Nexium tab 40mg, bid for 2weeks
Yonsei University Health System(Severance Hospital)
Seoul, Seodaemun-gu,Sinchon-dong, South Korea
Area under the plasma concentration versus time curve of YH4808
Time frame: Blood sampling during 0 ~ 24 hrs after administration
Peak plasma concentration of YH4808
Time frame: Blood sampling during 0~24 hrs after administration
Time to reach peak plasma concentration of YH4808
Time frame: Blood sampling during 0 ~ 24 hrs after administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Group 4 1. adminitration of Nexium tab 40mg, bid for 2weeks 2. wash-out period for 3weeks between period1 and period2 3. adminitration of YH4808 dose2, bid for 2weeks